Biologics for rheumatoid arthritis: An overview of Cochrane reviews

Sao Paulo Medical Journal

Volumn 128, Issue 5, 2010, Pages 309-310

  Singh, Jasvinder A ^a   Christensen, Robin ^a   Wells, George A ^a   Suarez Almazor, Maria E ^a   Buchbinder, Rachelle ^a   Lopez Olivo, Maria Angeles ^a   Ghogomu, Elizabeth Tanjong ^a   Tugwell, Peter ^a  

^a Centro Cochrane do Brasil   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

BIOLOGICAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 78650834275     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-31802010000500013     Document Type: Review

References (2)

1. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;(4):CD007848.
2. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.